TransCode Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
6 Liberty Sq Pmb 2382, Boston, Massachus...Phone Number
(857) 837-3099Revenue
-Stock Symbol
RNAZIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
1
About TransCode Therapeutics
TransCode Therapeutics is a biotechnology research and development company focused on RNAi oncology solutions. Founded in 2016 and headquartered in Boston, Massachusetts, the company specializes in discovering and developing innovative diagnostics and therapeutics for cancer detection and treatment, with particular emphasis on addressing metastasis. TransCode Therapeutics aims to advance data-driven cancer diagnostics and targeted treatment solutions through their pipeline of RNAi-based technologies. The company operates across multiple locations and serves the healthcare and medical research sectors with their specialized oncology products and services.Explore more
TransCode Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is TransCode Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
TransCode Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at TransCode Therapeutics
Check if TransCode Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when TransCode Therapeutics launches new products
Check out if TransCode Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once TransCode Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on TransCode Therapeutics recently announced quarterly report
Click to see if TransCode Therapeutics had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined TransCode Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to TransCode Therapeutics
Compare insights from companies similar to TransCode Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
TransCode Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
TransCode Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about TransCode Therapeutics.
TransCode Therapeutics financials insights
Gather financial insights about TransCode Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Share Placement
$10M
Debt
$25M
TransCode Therapeutics Tech Stack
A closer look at the technologies used by TransCode Therapeutics
See more technologies
Most Recent Scoops
Project
Product Development, Product Management, Medical Research, Pharmaceuticals, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
Funding
Project
Spending/Investment, Funding
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Funding
Funding
TransCode Therapeutics News & Media
TransCode Therapeutics (RNAZ) holder moves toward controlling stake via conversions
Major holder DEFJ, LLC reports beneficial ownership of 14,134,481 TransCode shares, or 83.9%, and plans to convert preferred stock after waiving a Beneficial Ownership Limitation.TransCode Therapeutics (NASDAQ: RNAZ) investor conversion leads to 9.9% stake
Major holder DEFJ converts 21.6755 Series B preferred shares into 216,755 common shares, reporting 300,040 shares, or 9.9% of TransCode Therapeutics’ 3,017,306 common shares outstanding.TransCode Therapeutics (RNAZ) investors approve share conversions and SEPA issuances
Shareholders representing 495,162 shares (52.1% voting power) back preferred stock conversions, SEPA and note issuances, director slate, auditor and Nasdaq-linked listing approvals.TransCode Therapeutics to Host R&D Webcast on June 18, 2026
Live Webcast to Highlight TTX-MC138 Phase 2a Trial, Three-Platform Pipeline, and Investment Thesis BOSTON, June 8, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage oncology company advancing a three-platform pipeline in RNA therapeutics and...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding TransCode Therapeutics
Sign Up For FreeTo access detailed company insights
TransCode Therapeutics is a biotechnology research and development company focused on RNAi oncology solutions. Founded in 2016 and headquartered in Boston, Massachusetts, the company specializes in discovering and developing innovative diagnostics and therapeutics for cancer detection and treatment, with particular emphasis on addressing metastasis... Read More
